Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Veterinary Medicine》 2012-08
Add to Favorite Get Latest Update

Efficacy of milbemycin oxime for the treatment of sarcoptic mange in dogs

XU Qian-qian1,2,LI Ji-chang3,GUO Shi-jin1,2,ZHANG Zhi-mei1,2, WANG Yan-ping1,2,ZHANG Ying1,2,SHEN Zhi-qiang1,2(1.Shandong Binzhou Animal Science and Veterinary Medicine Academy,Binzhou 256600,China; 2.Shandong Lvdu Ante Veterinary Drug Industry Co.,Ltd,Binzhou 256600,China; 3.College of Veterinary Medicine,Northeast Agricultural University,Harbin 150030,China)  
Milbemycin oxime tablets were evaluated for efficacy against sarcoptic mange mites in naturally infected dogs.Sixty-five dogs were randomly allocated to four groups and were housed individually.Five of the dogs were treated orally with ivermectin at the proposed dose.The other sixty dogs were treated with milbemycin oxime at the proposed minimum,middle and maximum doses(0.5 g/kg,1.0 g/kg and 2.0 g/kg).To enumerate Sarcoptes scabiei mites,skin scrapings were taken on Day 2,14,28,42 and 56.Clinical signs of mange and the extent of Sarcoptic lesions were evaluated on each dog when scrapings were made.Evaluation of the efficacy of the treatment was based on the absence of mites supported by the absence of clinical signs associated with canine sarcoptic mange.Treatment with maximum dose rate of milbemycin oxime at weekly intervals and ivermectin resulted in a rapid reduction of mites and improved clinical signs.The overall cure rates at Day 56,based on zero mite counts and resolution of clinical signs were 100%,while treatment with middle and minimum dose rate of milbemycin oxime at weekly intervals resulted in relative poor results.Weekly treatment with maximum dose(2.0 g/kg) rate of milbemycin oxime for continually three weeks,was effective for the treatment of sarcoptic mange in dogs.
【Fund】: “十一五”国家科技支撑计划项目(2006BAD31B02)
【CateGory Index】: S858.292
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Citations】
Chinese Journal Full-text Database 2 Hits
1 YU Xiao-lei,LI Ji-chang,ZHANG Yao-teng,QU Ming-li,XIANG Wen-sheng(College of Veterinary Medicine,Northeast Agricultural University,Harbin 150030;China);Therapeutic Observation of Milbemycin Oxime Tablet on Toxocara canis and Ancylostoma caninum[J];Chinese Journal of Veterinary Drug;2011-04
2 ZHANG Yao-teng1,YU Xiao-lei1,QU Ming-li1,XIANG Wen-sheng1,CHEN Guo-qing2,LI Rui1,LI Ji-chang1(1.College of Veterinary Medicine,Northeast Agricultural University,Harbin 150030,China;2.Zhejiang Hisun Pharmaceutical CO.,Ltd.Taizhou 318000,China);Effect of milbemycin oxime pellet on the haematological indexes in dogs[J];Chinese Journal of Veterinary Medicine;2011-05
【Co-citations】
Chinese Journal Full-text Database 2 Hits
1 GUO Shi-jin1,2,XU Qian-qian1,2,ZHANG Zhi-mei1,2,SHEN Zhi-qiang1,2*(1.Binzhou Academy of Animal Science and Veteringry Medicine,Binzhou,Shandong 256600,China; 2.Shandong Lvdu Ante Veterinary Drug Industry Co.,Ltd,Binzhou,Shandong 256600,China);P-glycoprotein and Application of Veterinary Drugs[J];Acta Ecologiae Animalis Domastici;2012-02
2 XU Qian-qian1,2,LI Ji-chang3,GUO Shi-jin1,2,ZHANG Zhi-mei1,2 WANG Yan-ping1,2,ZHANG Ying1,2,SHEN Zhi-qiang1,2(1.Shandong Binzhou Animal Science and Veterinary Medicine Academy,Binzhou 256600,China; 2.Shandong Lvdu Ante veterinary drug Industry Co.,Ltd,Binzhou 256600,China; 3.College of Veterinary Medicine,Northeast Agricultural University,Harbin 150030,China);Relative bioavailability of milbemycin oxime in dogs by oral administrate[J];Chinese Journal of Veterinary Medicine;2012-09
【Secondary Citations】
Chinese Journal Full-text Database 1 Hits
1 XU Qian-qian,LI Ji-chang,XIANG Wen-sheng,ZHANG Yao-teng,QU Ming-li,YU Xiao-lei(College of Veterinary Medicine,Northeast Agricultural University,Harbin 150030;China);Research Progress on Milbemycin Oxime[J];Chinese Journal of Veterinary Drug;2009-07
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved